Side Effects to Monitor on Coumadin
The most critical side effect to monitor is bleeding, which is directly related to anticoagulation intensity and represents the primary life-threatening complication of warfarin therapy 1, 2.
Primary Side Effect: Bleeding
Major Bleeding Risk Factors
Monitor patients particularly closely if they have 1:
- Age ≥65 years (elderly are more prone to bleeding even at therapeutic INR levels)
- History of stroke or gastrointestinal bleeding
- Renal insufficiency or anemia
- Concomitant use of antiplatelet agents (aspirin, NSAIDs) or other drugs affecting platelet function
- Multiple risk factors are additive - patients with 2-3 risk factors have substantially higher bleeding incidence
Bleeding Manifestations to Watch For
Instruct patients to report 2, 3:
- Superficial bleeding: Ecchymosis (easy bruising), petechiae, bleeding gums, nosebleeds
- Internal bleeding: Melena (black tarry stools), hematuria (blood in urine), hematemesis (vomiting blood)
- Serious bleeding: Intracranial hemorrhage symptoms (severe headache, confusion, weakness), hemoptysis (coughing blood)
- Gastrointestinal symptoms that may indicate GI bleeding
INR Monitoring Strategy
The INR value is the most significant predictor of adverse events 3, 4:
- INR >3.0 serves as a reliable trigger for potential bleeding complications
- Obtain daily INR until stable in therapeutic range (typically 2.0-3.0)
- Once stable, check INR every 1-4 weeks 2
- Any INR >5 requires intervention even without active bleeding 1
Critical Non-Hemorrhagic Side Effects
Skin Necrosis (Life-Threatening)
This is the most important non-bleeding complication 1, 5:
- Typically occurs on days 3-8 of therapy
- Caused by extensive thrombosis of venules and capillaries in subcutaneous fat
- Associated with protein C deficiency but can occur in anyone
- Warfarin is contraindicated if this occurs - requires immediate discontinuation
- Presents as painful, purple-black skin lesions, often on breasts, buttocks, thighs
Limb Gangrene
A variant of skin necrosis involving massive venous outflow obstruction 5:
- Particularly in cancer-associated DVT patients
- Can occur in patients with heparin-induced thrombocytopenia transitioned to warfarin
Purple Toe Syndrome
Rare complication occurring 3-8 weeks after initiation 5:
- Bilateral, painful purple lesions on toes and sides of feet
- Blanches with pressure
- Due to cholesterol emboli, not bleeding
Common But Less Serious Side Effects
Monitor for 3:
- Nausea
- Dizziness
- Stomach ache/abdominal discomfort
- Hair loss (alopecia diffusa)
- Urticaria and allergic reactions
Drug and Dietary Interactions Requiring Vigilance
High-Risk Drug Interactions
Closely monitor INR when starting or stopping 2:
- Antibiotics and antifungals - can dramatically alter INR
- NSAIDs - increase bleeding risk through platelet inhibition and GI erosions 6
- Antiplatelet agents (aspirin, clopidogrel)
- SSRIs (serotonin reuptake inhibitors)
- CYP2C9, 1A2, or 3A4 inhibitors/inducers
High-Risk Food/Herbal Interactions
Counsel patients to avoid or use extreme caution with 7:
- Increased bleeding risk: Cranberry, ginkgo biloba, ginger, garlic, green tea, chamomile tea, cannabis, St. John's Wort
- Variable INR effects: Foods high in vitamin K (spinach, kale, broccoli) - consistency is key, not avoidance
- Smoking tobacco can affect warfarin metabolism
Common Pitfalls to Avoid
Don't assume therapeutic INR means no bleeding risk - bleeding at INR 2.0-3.0 often indicates underlying lesions (GI tract, urinary tract) that require investigation 1
Elderly patients require lower initial doses - they have higher bleeding risk independent of INR level 1
Never ignore INR 5-9 even without bleeding - this requires intervention (hold doses, consider vitamin K) as it predicts imminent bleeding 1
Monitor more frequently during antibiotic courses - even short courses can dramatically affect INR 2
Warfarin is absolutely contraindicated in pregnancy except in women with mechanical heart valves where benefits may outweigh risks 2 - it causes CNS malformations in 10-30% of exposed fetuses 1